MedPath

REcommened Communication With Sympathy in Terminally Ill Cancer Patients Treated With Palliative Sedation

Phase 2
Conditions
Communication, Palliative Sedation
Interventions
Other: healthcare provider's recommended communication with sympathy and printed paper
Registration Number
NCT04642677
Lead Sponsor
Pusan National University Yangsan Hospital
Brief Summary

* In terminally ill cancer patients, palliative sedation has been applied to intractable refractory symptoms such as pain, dyspnea, delirium, agitation.

* Palliative sedation is generally an adaptive strategies using midazolam, which is composed of intermittent bolus, limited continuous, or 24hr continuous infusion depending on the time of drug application.

* In the application of palliative sedation, caregiver's negative feelings such as anxiety or guilt for palliative sufficiency are one of the biggest challenges as the patient's consciousness is reduced, and they feels disconnected from the patient.

* In general, hearing is known to persist until the very last moment of the end of life, regardless of consciousness. In addition, maintaining communication with patients and caregivers is the most important part of the hospice.

* This study evaluate the efficacy of healthcare provider's recommended communication with sympathy, "Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end."

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
62
Inclusion Criteria
  • Patients who are expected to die within a few weeks due to disease progression without additional anti-tumor treatment plans.
  • Patients who are the target of palliative sedation because intractable symptom such as pain, dyspnea, delirium, or agitation persist as even after the conservative treatment.
  • Patients who have agreed to palliative sedation.
Exclusion Criteria
  • Patients treated with a palliative sedation methods using bolus application or other drugs (lorazepam, etc.) rather than continuous midazolam were excluded.
  • In case of the guardian is unable to stay with the patient for more than 6 hours per day, the patients were excluded.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group Ahealthcare provider's recommended communication with sympathy and printed paperPatients and caregivers were received palliative sedation with healthcare provider's recommended communication with sympathy and printed paper, "Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end." three times a day (8, 14 and 20 o'clock).
Primary Outcome Measures
NameTimeMethod
Complete response rate of palliative sedationFrom date of enrollment until death or discharge/transfer, assess up to 2 years

Rate of cases (death or multiogran failure) among all causes (death, multi-organ failure, failure of sedation level, palliative sedation related adverse events, caregiver's refuse, or others) as discontinuation causes of palliative sedation

Discontinuation rate of palliative sedation irrespective of physicianFrom date of enrollment until death or discharge/transfer, assess up to 2 years

Rate of cases (caregiver's refuse or others) among all causes (death, multi-organ failure, failure of sedation level, palliative sedation related adverse events, caregiver's refuse, or others) as discontinuation causes of palliative sedation

Secondary Outcome Measures
NameTimeMethod
Anxiety of caregiver2th to 7th day after enrollment

GAD-7 (General Anxiety Disorder-7)

Satisfaction of caregiver2th to 7th day after enrollment

How is your satisfaction with the IV access so far?" (rated as "much comfort", "a little comfort", "no change", "a little discomfort", or "much discomfort")

Palliative sedation related Adverse eventsFrom date of enrollment until death or discharge/transfer, assess up to 2 years

Adverse events related with palliative sedation using CTCAE 4.3

Trial Locations

Locations (1)

Pusan National University Yangsan Hospital

🇰🇷

Yangsan, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath